ArticleJournal of pharmaceutical policy and practice2022
Exploration of facilitators and barriers to the regulatory frameworks of dietary and herbal supplements: a scoping review.
Article in Journal of pharmaceutical policy and practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Obesity and Natural Products: Mechanisms, Therapeutic Potential, and Future Directions.Food science & nutrition · 2026Review
- Chemical Signaling and Metabolomic Crosstalk in Endophytic Fungi-Medicinal Plant Symbioses for Natural Product Discovery and Sustainable Bioproduction.Metabolites · 2026Review
- Regulation of Food Supplements and Pharmacists' Responsibility in Professional Practice: A Review.Pharmacy (Basel, Switzerland) · 2026Review
- Challenges in performing clinical research on herbal products - experiences from Switzerland and the UK.Frontiers in pharmacology · 2026Article
- WHO global research priorities for traditional, complementary, and integrative (TCI) medicine: an international consensus and comparisons with LLMs.Journal of global health · 2025Article
- Targeting Ocular Biofilms with Plant-Derived Antimicrobials in the Era of Antibiotic Resistance.Molecules (Basel, Switzerland) · 2025Review
- Traditional medicine regulation status and challenges in Malawi and Nigeria.BMC complementary medicine and therapies · 2025Article
- The safety of herbal medicines in low- and middle-income countries (LMICs): current landscape and promoting the pharmacovigilance practices.Journal of pharmaceutical policy and practice · 2025Article
- Traditional herbal medicine legislative and regulatory framework: a cross-sectional quantitative study and archival review perspectives.Frontiers in pharmacology · 2025Article
- Cultural and religious structures influencing the use of maternal health services in Nigeria: a focused ethnographic research.Reproductive health · 2024Article
- Medicinal Values and Potential Risks Evaluation ofMolecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOver the last decade, the use of dietary and herbal supplements (DHSs) has expanded greatly across national healthcare settings for the prevention, management and/or treatment of a variety of health issues. Although regulatory policies for DHSs across different countries have been aimed towards evaluating safety and efficacy, performing quality controls, monitoring the manufacturing practices, and encouraging further research, significant safety issues have emerged from inappropriate regulatory classification, lack of suitable quality controls, and inadequate testing and labeling of these products. Therefore, the purpose of this scoping review was to identify facilitators and barriers to DHS regulation across different countries.
methodsA scoping review was conducted and informed by the five-stage methodological framework proposed by Arksey and O'Malley and further enhanced by Levac et al. MEDLINE, EMBASE, AMED, and PsycINFO databases were systematically searched for eligible articles from database inception to September 29, 2020. Studies analyzing DHS regulatory frameworks were eligible for review. Relevant data from eligible articles were extracted and categorized into themes to provide a descriptive overview of the literature.
resultsSearches generated 4314 results, 1800 of which were duplicates, followed by 2472 that were excluded after screening the titles and abstracts of these articles. Of the remaining 42 full-texts, 15 eligible articles were included in this review. Themes identified include: (1) increased financial and human resources encouraging knowledge expansion as a facilitator to DHS regulation; (2) variances in DHS classification and regulatory requirements across countries as a barrier to DHS regulation, and (3) collaboration between various stakeholders (experts, policymakers, representatives of regulatory bodies, product companies and research institutions) facilitating DHS regulation.
conclusionThe present scoping review identified facilitators and barriers to DHS regulation across different countries. We highlight that safety assessments of DHSs continue to be inadequate, and emerging technologies could potentially play a significant role in establishing common reference standards of herbal materials and products between regulatory agencies. Regulatory harmonization, increased scientific research, and collaboration could improve regulations globally through appropriate categorization and safe application of DHSs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.